News

A neurologist’s main goal is promoting optimal healing after a concussion, but pressure to return athletes to play can make treatment difficult.

How can a clinician best treat a young athlete more concerned with return to play than with his or her health?

New PD medications and treatments are being developed and novel uses for existing drugs are being discovered.

Is fatigue with MS related to diet? Is alcohol intake tied to lower MS disability and severity? Researchers at AAN 2015 reported on how patients are affected by what they eat and drink.

Find the latest developments in epilepsy research on the pages that follow and test your knowledge by answering some of the difficult questions.

Graph theory applied to epilepsy, an abbreviated QOLCE, promising new interventions for neonatal seizures, a minipump to deliver drugs-the latest developments in epilepsy diagnosis and patient care.

Proteins linked in a pathway, drugs that may prevent memory loss, the positive role of sleep, a new memory app-check out these latest new concepts in AD diagnosis and treatment.

Potential approaches to devising strategies that may allow amelioration of this disease are revealed in a recent study. But questions remain.

Worse strokes are more likely to occur in patients who are resistant to aspirin. Better ways to identify those patients are needed.

This new guideline could change the approach many physicians take to treating a first seizure--and could improve patients’ lives.

Deep brain stimulation, stem cell treatment, studying mitochondria-to mark Parkinson’s Awareness Month, we review some noteworthy new concepts.

Advances in neurology science and patient care continue to make news even before the doors to the AAN 2015 Annual Meeting officially open on Saturday. These are the top stories.

The SPG is a promising target for migraine treatment, but robust evidence of efficacy for routine use of noninvasive device–mediated SPG blockade is needed.

A new way to treat dementia and other diagnosis and treatment developments are in the news.

A switch to a second-line drug in a patient receiving first-line therapies likely will be effective at decreasing disease activity.

While a majority of persons with the 4 most common cancers are told the diagnosis, fewer than half of persons with AD get that kind of information. This could be a problem.

There’s a new app for tracking symptoms of Parkinson disease, Alzheimer and Parkinson diseases may share characteristics with mad cow disease, and a skin test may one day be used to detect both AD and PD.

An FDA-approved drug for high blood pressure alleviates clinical symptoms of MS in mice, showing great promise for humans.

Focused ultrasound works like a noninvasive knife, cutting away amyloid plaques in mice. But is this new method safe and effective in humans?

Noninvasive measurements of cerebral hemodynamics and oxygenation can have a significant impact on the assessment of cerebrovascular conditions and can monitor the effects of clinical procedures on brain circulation.

Efficacy of acute medication matters beyond just treating a single migraine. It may increase the risk of worsened disease.

These agents lower cholesterol and prevent cardiovascular disease, but they may actually increase the risk of Parkinson disease. Caution advised.

The ultimate cause is found in only about half of patients, so improved understanding of the prognostic and diagnostic features is of high priority.

This treatment may be superior to current treatment for patients with severe multiple sclerosis that is not responding well to standard treatments.

Drugs often involve multiple daily doses with complex dosing regimens, but interventions that have been applied generically to patients with chronic diseases can be applied to these cases as well.

Favorable long-term results for patients with hard-to-treat epilepsy who undergo brain surgery offer good information for decision-making and counseling.

There is no approved screening tool for misophonia, but a case review can lead to a diagnosis. Several treatment options may aid in symptom management.

Scientists are testing alternative therapeutic approaches that may delay disease progression and even protect and regenerate neurons.

Anticholinergics could confer an increased risk, one dependent on the dose and amount of use. Give them to older patients or consider alternatives?